Tetsuya Hosooka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tetsuya Hosooka has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Wataru Ogawa
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
4 shared publications Wataru Ogawa
Kobe Univ, Dept Internal Med, Div Diabet & Endocrinol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
3 shared publications- Kazuhiro Nomura
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2 shared publications - Yu Hirata
Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2 shared publications Chikako Aoki
Kobe Univ, Dept Internal Med, Div Diabet & Endocrinol, Grad Sch Med, Kobe, Hyogo 6500017, Japan
1 shared publication- Daisuke Kato
Department of Physiology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 16 May 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (10) , 1-13
A Piezo1/KLF15/IL-6 axis mediates immobilization-induced muscle atrophy
Although immobility is a common cause of muscle atrophy, the mechanism underlying this causality is unclear. We here show that Krüppel-like factor 15 (KLF15) and IL-6 are upregulated in skeletal muscle of limb-immobilized mice and that mice with KLF15 deficiency in skeletal muscle or with systemic IL-6 deficiency are protected from immobility-induced muscle atrophy. A newly developed Ca2+ bioimaging revealed that the cytosolic Ca2+ concentration ([Ca2+]i) of skeletal muscle is reduced to below the basal level by immobilization, which is associated with the downregulation of Piezo1. Acute disruption of Piezo1 in skeletal muscle induced Klf15 and Il6 expression as well as muscle atrophy, which was prevented by antibodies against IL-6. A role for the Piezo1/KLF15/IL-6 axis in immobility-induced muscle atrophy was validated in human samples. Our results thus uncover a paradigm for Ca2+ signaling in that a decrease in [Ca2+]i from the basal level triggers a defined biological event.
- 16 May 2022
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 132 (10) , 1-13
Top Cited PapersOpen AccessA Piezo1/KLF15/IL-6 axis mediates immobilization-induced muscle atrophy
Although immobility is a common cause of muscle atrophy, the mechanism underlying this causality is unclear. We here show that Krüppel-like factor 15 (KLF15) and IL-6 are upregulated in skeletal muscle of limb-immobilized mice and that mice with KLF15 deficiency in skeletal muscle or with systemic IL-6 deficiency are protected from immobility-induced muscle atrophy. A newly developed Ca2+ bioimaging revealed that the cytosolic Ca2+ concentration ([Ca2+]i) of skeletal muscle is reduced to below the basal level by immobilization, which is associated with the downregulation of Piezo1. Acute disruption of Piezo1 in skeletal muscle induced Klf15 and Il6 expression as well as muscle atrophy, which was prevented by antibodies against IL-6. A role for the Piezo1/KLF15/IL-6 axis in immobility-induced muscle atrophy was validated in human samples. Our results thus uncover a paradigm for Ca2+ signaling in that a decrease in [Ca2+]i from the basal level triggers a defined biological event.
- 1 June 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 557, 62-68
Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
- 1 June 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 557, 62-68
Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E2
- Top Cited Papers
- 21 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (4)
Hyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
Diabetes mellitus is associated with various disorders of the locomotor system including the decline in mass and function of skeletal muscle. The mechanism underlying this association has remained ambiguous, however. We now show that the abundance of the transcription factor KLF15 as well as the expression of genes related to muscle atrophy are increased in skeletal muscle of diabetic model mice, and that mice with muscle-specific KLF15 deficiency are protected from the diabetes-induced decline of skeletal muscle mass. Hyperglycemia was found to upregulate the KLF15 protein in skeletal muscle of diabetic animals, which is achieved via downregulation of the E3 ubiquitin ligase WWP1 and consequent suppression of the ubiquitin-dependent degradation of KLF15. Our results revealed that hyperglycemia, a central disorder in diabetes, promotes muscle atrophy via a WWP1/KLF15 pathway. This pathway may serve as a therapeutic target for decline in skeletal muscle mass accompanied by diabetes mellitus.
- 21 February 2019
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (4)
Top Cited PapersHyperglycemia induces skeletal muscle atrophy via a WWP1/KLF15 axis
Diabetes mellitus is associated with various disorders of the locomotor system including the decline in mass and function of skeletal muscle. The mechanism underlying this association has remained ambiguous, however. We now show that the abundance of the transcription factor KLF15 as well as the expression of genes related to muscle atrophy are increased in skeletal muscle of diabetic model mice, and that mice with muscle-specific KLF15 deficiency are protected from the diabetes-induced decline of skeletal muscle mass. Hyperglycemia was found to upregulate the KLF15 protein in skeletal muscle of diabetic animals, which is achieved via downregulation of the E3 ubiquitin ligase WWP1 and consequent suppression of the ubiquitin-dependent degradation of KLF15. Our results revealed that hyperglycemia, a central disorder in diabetes, promotes muscle atrophy via a WWP1/KLF15 pathway. This pathway may serve as a therapeutic target for decline in skeletal muscle mass accompanied by diabetes mellitus.
- 1 April 2016
- p. 405-10
[Molecular mechanism underlying cancer development in diabetes].
- Open Access
- 8 June 2015
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 7 (1) , 27-28
A novel role for the cell cycle regulatory complex cyclin D1–CDK4 in gluconeogenesis
Dysregulation of gluconeogenesis is a key pathological feature of type 2 diabetes. However, the molecular mechanisms underlying the regulation of gluconeogenesis remain unclear. Bhalla et al. recently reported that cyclin D1 suppresses hepatic gluconeogenesis through CDK4-dependent phosphorylation of PGC1alpha and consequent inhibition of its activity. The cyclin D1-CDK4 might thus serve as an important link between the cell cycle and control of energy metabolism through modulation of PGC1alpha activity.
- 8 June 2015
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 7 (1) , 27-28
Open AccessA novel role for the cell cycle regulatory complex cyclin D1–CDK4 in gluconeogenesis
Dysregulation of gluconeogenesis is a key pathological feature of type 2 diabetes. However, the molecular mechanisms underlying the regulation of gluconeogenesis remain unclear. Bhalla et al. recently reported that cyclin D1 suppresses hepatic gluconeogenesis through CDK4-dependent phosphorylation of PGC1alpha and consequent inhibition of its activity. The cyclin D1-CDK4 might thus serve as an important link between the cell cycle and control of energy metabolism through modulation of PGC1alpha activity.
- Open Access
- 6 May 2013
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 4 (6) , 525-527
Vascular endothelial growth factor‐B as a therapeutic target to prevent ectopic fat deposition
- 6 May 2013
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 4 (6) , 525-527
Open AccessVascular endothelial growth factor‐B as a therapeutic target to prevent ectopic fat deposition
- 1 January 2011
- p. 290-4
[Mechanism of insulin resistance caused by hepatic inflammation].